At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
PF-04965842drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE STUDY TO COMPARE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF PF-04965842 IN ADULT SUBJECTS WITH MILD AND MODERATE HEPATIC IMPAIRMENT RELATIVE TO SUBJECTS WITH NORMAL HEPATIC FUNCTION
In Brief
A Phase 1 clinical trial evaluating PF-04965842 for Hepatic Impairment. Completed, enrolled 24 participants across 2 sites.
Detailed Summary
This is a Phase 1 non randomized, open label, single dose, parallel cohort study to investigate the effect of hepatic impairment on the PK, safety and tolerability of PF 04965842.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatic Impairment
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartOct 2018
Primary CompletionApr 2019
TodayJul 2026
First PostedAug 13, 2018
Enrollment StartOct 1, 2018
Primary CompletionApr 30, 2019
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 7.9 years ago
Interventions
PF-04965842drug
PF 04965842 is an orally bioavailable small molecule that selectively inhibits JAK1.